for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novo Nordisk A/S

NOVOb.CO

Latest Trade

381.45DKK

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

291.80

 - 

393.70

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
381.45
Open
--
Volume
--
3M AVG Volume
52.25
Today's High
--
Today's Low
--
52 Week High
393.70
52 Week Low
291.80
Shares Out (MIL)
2,343.56
Market Cap (MIL)
712,244.50
Forward P/E
23.28
Dividend (Yield %)
2.13

Next Event

Novo Nordisk A/S at Citi Global Healthcare Conference

Latest Developments

More

Novo Nordisk Expects To Meet Long-Term Financial Targets

Dicerna And Novo Nordisk Enter Deal To Discover And Develop RNAi Therapies

Novo Nordisk Obtains Licence From UBE Industries

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry

Biotechnology & Drugs

Contact Info

Novo Alle

+45.44.448888

https://www.novonordisk.com/

Executive Leadership

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Jeppe Christiansen

Vice Chairman of the Board

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Maziar Mike Doustdar

Executive Vice President, International Operations

Key Stats

2.50 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2016

111.8K

2017

111.6K

2018

111.8K

2019(E)

121.1K
EPS (DKK)

2017

15.390

2018

15.930

2019(E)

16.468
Price To Earnings (TTM)
23.59
Price To Sales (TTM)
5.97
Price To Book (MRQ)
16.92
Price To Cash Flow (TTM)
15.96
Total Debt To Equity (MRQ)
8.20
LT Debt To Equity (MRQ)
5.53
Return on Investment (TTM)
67.78
Return on Equity (TTM)
34.15

Latest News

Latest News

Novo Nordisk nudges up 2019 sales outlook as new drugs excel

Novo Nordisk <NOVOb.CO> posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs.

Drugmaker Novo Nordisk's Q3 operating profit slightly lags forecast

Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday but nudged up its sales outlook for this year on the back of its new drugs for type 2 diabetes and obesity.

Novo Nordisk targets bigger slice of diabetes market with new tablet

Danish drugmaker Novo Nordisk <NOVOb.CO> is aiming for a big slice of the multibillion-dollar diabetes market with a new pill, approved by U.S. authorities on Friday, that caters for patients with an aversion to needles.

UPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug

The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment.

FDA approves oral diabetes drug from Novo Nordisk

The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment.

Novo Nordisk to cut insulin prices in the U.S.

Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.

Novo Nordisk to cut insulin prices for some U.S. diabetics

Novo Nordisk said on Friday it would offer cheaper insulin to some U.S. diabetics in response to intense criticism over the high price of the medication and following similar moves by rivals Sanofi and Eli Lilly.

Denmark's Novo Nordisk files lawsuit against Mylan over patent

Novo Nordisk <NOVOb.CO> said on Thursday it has filed litigation in a Delaware district court against Mylan <MYL.O> aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Novo Nordisk contests Danish lawsuit claiming $1.75 billion

Danish insulin-maker Novo Nordisk <NOVOb.CO> said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement.

Novo Nordisk sued in Denmark for alleged market manipulation - media

Danish insulin-maker Novo Nordisk has been sued by investors demanding 11.8 billion Danish crowns ($1.8 billion) in compensation for the company's alleged market manipulation, Danish daily Borsen reported on Friday.

Novo Nordisk's new diabetes, obesity drugs lift sales outlook

Novo Nordisk <NOVOb.CO> raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline.

Diabetes drug maker Novo Nordisk buys pill factory in North Carolina

Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes.

BRIEF-Novo Nordisk: PIONEER 6 Trial Achieved Its Primary Endpoint

* SAID ON TUESDAY THE PIONEER 6 TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING NON-INFERIORITY OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO, BOTH IN ADDITION TO STANDARD OF CARE

Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study

An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday.

Novo Nordisk profit tops forecast as new diabetes drug shines

Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes.

Drugmaker Novo Nordisk first-quarter profit beats expectations

Danish drugmaker Novo Nordisk posted first-quarter operating profit above forecasts on Friday as it sold more of its newest innovative drug to combat diabetes and nudged up its 2019 outlook reported in Danish crowns.

Novo Nordisk and Gilead team up to test fatty liver disease treatment

Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Only first whistleblower entitled to collect in Novo Nordisk settlement – judge

A former Novo Nordisk employee deserves 15 percent of a $46.5 million settlement between the drugmaker and the U.S. Justice Department resolving claims its marketing downplayed its diabetes medication Victoza's cancer risks, a federal judge has ruled.

Novo Nordisk submits diabetes pill for U.S. approval

Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for approval in the United States.

Novo Nordisk submits diabetes pill for U.S. approval

Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up